UNDERWRITING AGREEMENT 1,372,213 Common Shares ONCOLYTICS BIOTECH Inc. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • June 1st, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative”), an aggregate of 1,372,213 common shares (each, a “Firm Share”), no par value, of the Company (the “Common Shares”). The Company also proposes to grant to the Underwriters an option to purchase up to 205,832 additional Common Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”). To the extent there are no additional Underwriters listed on Schedule I hereto, the term “Representative” as used herein shall mean Ladenburg Thalmann & Co. Inc. as Underwriter and the term “Underwriters” shall be construed as singular.
